他克林治疗阿尔采末病:在中国的多中心双盲研究

目的：验证他克林治疗轻至中度阿尔采末病（ＡＤ）的疗效。方法：轻至中度ＡＤ病人６８例完成验证，其中３４例（男性１８例，女性１６例，年龄６７ａ±７ ａ）用他克林自 １０ ｍｇ，ｐｏ， ｑｉｄ起，另外 ３４例（男性 １８例，女性 １６例，年龄 ６７ ａ±９ ａ）用安慰剂（淀粉）自 １０ ｍｇ，ｐｏ， ｑｉｄ起。 ２组每 ６ Ｗｋ日量各增加 ４０ｍｇ，最高日量 ４０ ｍｇ，ｐｏ， ｑｉｄ。总疗程均为２４ ｗｋ。结果：他克林组在认知功能、日常生活及总体疗效方面改善率均显著高于安慰剂组（ Ｐ＜ ０． ０５或０．０１），他克林副作用主要为胃肠道反应，包括ＡＬＴ升高（１４％）。结论：他克林治疗轻至中度ＡＤ病人有效。

Tacrine in treatment of Alzheimer disease: a multicenter, double-blind study in China

AIM: To evaluate the clinical efficacy of tacrine in treating mild to moderate Alzheimer disease (AD ). METHODS: Sixty-eight Patients with mild to moderate AD completed the trial. Thirty-four patients (M18, F16; age 67 a ± s 7 a) were treated with tacrine, initiated from 10 mg, po, qid. The other thirty-four patients (M 18, F 16; age 67 a ± 9 a) were treated with placebo (starch), initiated from 10 mg, po, qid. The daily doses of both groups were augmented 40 mg every six weeks and the highest doses were 40 mg, po, qid. The whole treatment lasted for 24 wk. RESULTS: Tacrine group showed much higher rates of improvement in terms of cognitive function, daily living and clinical global impression than those of placebo group (P < 0.05 or P < 0.01). Side effects of tacrine involve mainly in the gastro-intestinal system, including the elevation of ALT(12% ). CONCLUSION: Tacrine is effective in treating mild to moderate AD patients.